BR9610314A - Immunosuppressive processes to prevent or treat autoimmune diseases in mammals and prevent graft rejection use of a compound pharmaceutical composition and use of it - Google Patents

Immunosuppressive processes to prevent or treat autoimmune diseases in mammals and prevent graft rejection use of a compound pharmaceutical composition and use of it

Info

Publication number
BR9610314A
BR9610314A BR9610314A BR9610314A BR9610314A BR 9610314 A BR9610314 A BR 9610314A BR 9610314 A BR9610314 A BR 9610314A BR 9610314 A BR9610314 A BR 9610314A BR 9610314 A BR9610314 A BR 9610314A
Authority
BR
Brazil
Prior art keywords
prevent
mammals
pharmaceutical composition
autoimmune diseases
graft rejection
Prior art date
Application number
BR9610314A
Other languages
Portuguese (pt)
Inventor
Haruhiro Makino
Takashi Sohda
Yoshikazu Ohta
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of BR9610314A publication Critical patent/BR9610314A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR9610314A 1995-09-13 1996-06-19 Immunosuppressive processes to prevent or treat autoimmune diseases in mammals and prevent graft rejection use of a compound pharmaceutical composition and use of it BR9610314A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23570495 1995-09-13
PCT/JP1996/001693 WO1997009984A1 (en) 1995-09-13 1996-06-19 Immunosuppressant

Publications (1)

Publication Number Publication Date
BR9610314A true BR9610314A (en) 1999-07-06

Family

ID=16990000

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9610314A BR9610314A (en) 1995-09-13 1996-06-19 Immunosuppressive processes to prevent or treat autoimmune diseases in mammals and prevent graft rejection use of a compound pharmaceutical composition and use of it

Country Status (10)

Country Link
EP (1) EP0850061A1 (en)
KR (1) KR19990044618A (en)
CN (1) CN1195988A (en)
AU (1) AU6137396A (en)
BR (1) BR9610314A (en)
CA (1) CA2226915A1 (en)
HU (1) HUP9900169A2 (en)
NO (1) NO980788L (en)
NZ (1) NZ310561A (en)
WO (1) WO1997009984A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0941987A1 (en) * 1998-03-13 1999-09-15 Lonza A.G. Process for the preparation of 2-Amino-4,5,3',4'-tetramethoxybenzophenone
EP1277740A1 (en) * 1998-06-12 2003-01-22 Vertex Pharmaceuticals Incorporated Inhibitors of p38
WO1999064400A1 (en) 1998-06-12 1999-12-16 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
DE19853487A1 (en) 1998-11-19 2000-05-25 Fumapharm Ag Muri Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
RU2313339C2 (en) 2003-09-09 2007-12-27 Фумафарм Аг Using derivatives of fumaric acid in treatment of cardiac insufficiency and asthma
DK2653873T3 (en) 2007-02-08 2022-07-25 Biogen Ma Inc Compositions and uses for the treatment of multiple sclerosis
CN102050780B (en) * 2010-11-18 2012-05-02 中国科学院昆明植物研究所 Quinoline derivatives, pharmaceutical compositions and uses thereof
WO2017151947A1 (en) * 2016-03-02 2017-09-08 George Robert Pettit 4-azapodophylotoxins compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0138919B1 (en) * 1987-08-26 1998-04-30 프레드릭 에이. 유스티스, 3세 Method of producing a recombinant dna molecule coding for an il-1 inhibitors
KR0148009B1 (en) * 1988-05-27 1998-08-01 그래고리 비. 아보트 Interleukin-1 inhibitors
JP2863265B2 (en) * 1989-05-19 1999-03-03 ハダサ メディカル オーガニゼーション Interleukin 1 inhibitor
US6238875B1 (en) * 1991-03-12 2001-05-29 The Scripps Research Institute Diagnostic methods useful in the characterization of lymphoproliferative disease characterized by increased EPR-1
TW232013B (en) * 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
US5646154A (en) * 1992-10-07 1997-07-08 Sumitomo Pharmaceuticals Co., Ltd. Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor
JPH06340658A (en) * 1993-04-08 1994-12-13 Kyowa Hakko Kogyo Co Ltd Benzimidazole derivative
IL111743A0 (en) * 1993-12-08 1995-01-24 Intermune Life Sciences Inc Recombinant genes expressing pp14

Also Published As

Publication number Publication date
NO980788L (en) 1998-03-31
EP0850061A1 (en) 1998-07-01
WO1997009984A1 (en) 1997-03-20
CA2226915A1 (en) 1997-03-20
NO980788D0 (en) 1998-02-25
KR19990044618A (en) 1999-06-25
CN1195988A (en) 1998-10-14
HUP9900169A2 (en) 2000-03-28
NZ310561A (en) 1999-07-29
AU6137396A (en) 1997-04-01

Similar Documents

Publication Publication Date Title
BR9612698A (en) Stable composition of avidin and processes for its use
BR9610248A (en) Compound pharmaceutical composition processes for the treatment of pain and for the preparation of a compound and use of the compound
BR9604632A (en) Aromatic bicyclic compounds use of at least one of the compounds pharmaceutical composition cosmetic composition and use of a cosmetic composition
BR9609532A (en) Antimicrobial composition for the treatment of hair process for the treatment of dandruff and use of the composition
BR9602856A (en) Composition of polysaccharide grafted method for the treatment of arthritis in mammals and for the preparation of polysaccharide grafted with antioxidant
BR9709915A (en) Compound pharmaceutical composition use of the compound and processes for the treatment or prevention of physiological disorders associated with an excess of tachykinins and for the preparation of the compound
DK0861666T3 (en) Pharmacological preparation for use in the treatment of diabetes
PT978276E (en) POLYMER COATING TABLETS COMPRISING AMOXYCYCLINE AND CLAVULANATE
BR9609831A (en) Antipruritic cosmetic and / or pharmaceutical compositions
FR2767697B1 (en) DERMATOLOGICAL COMPOSITION FOR PREVENTING THE APPEARANCE OF SKIN HYPERSENSITIVITY AND INTOLERANCE SYMPTOMS
BR9610314A (en) Immunosuppressive processes to prevent or treat autoimmune diseases in mammals and prevent graft rejection use of a compound pharmaceutical composition and use of it
BR9711311A (en) Compound pharmaceutical composition use of a compound and processes for the preparation of compounds and for the treatment of a mammal including man
BR9604631A (en) Aromatic bicyclic compounds use of compounds pharmaceutical composition cosmetic composition and their use
BR9707720A (en) Peptide derivative or a pharmaceutically acceptable salt of the same pharmaceutical composition. Processes for making a peptide derivative or a pharmaceutically acceptable salt thereof and for treating an autoimmune or inflammatory disease and use of a peptide derivative or a pharmaceutically acceptable salt thereof.
BR9710376A (en) Antiviral compound use of the same pharmaceutical composition and process for prophylactic or therapeutic antiviral treatment of a human or non-human animal
BR9610733A (en) Compound processes for the preparation of it and for the treatment of a mammal pharmaceutical composition and use of a compound
IL119459A0 (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
PT898566E (en) SUBSTITUTED BENZYLAMINES AND THEIR USE IN TREATMENT OF DEPRESSION
MX9100856A (en) ROTOGRANULATIONS AND TASTE MASKING COATINGS FOR THE PREPARATION OF CHEWABLE PHARMACEUTICAL TABLETS
FR2758003B1 (en) ANTI-REFLECTIVE TREATMENT OF REFLECTIVE SURFACES
PT874839E (en) DERIVATIVES OF FURANO- AND TIOFENO-CARBOTIAMAMES HIS PREPARATION AND ITS USE AS INHIBITORS OF THE REPLICATION OF HIV-1 AND HIV-1 MUTANTS
BR9608407A (en) Use of a pharmaceutical preparation compound for use in the prophylaxis and / or treatment of multiple system organ failure and process for prophylaxis and treatment of multiple system organ failure in mammals including man
BR9607169A (en) Use of meletonin and pharmaceutical formulation for use in the treatment of a multiple drug addict
AU4762893A (en) Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases.
FR2729871B1 (en) SPRAY PARTS TREATMENT CABIN

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FA8 Dismissal: dismissal - article 36, par. 1 of industrial property law